A truncated recombinant spike protein (ΔTM S protein) of SARS coronavirus (SARS-CoV) was investigated as a vaccine in formulation with either the proprietary adjuvant Protollin (ProT) or with Alhydrogel. In young mice intranasal (i.n.) immunization with Protollin-formulated ΔTM S protein elicited a high level of specific serum IgG and neutralizing antibody. Intramuscular (i.m.) administered Alhydrogel vaccine achieved similar results. In a challenge study, mice immunized i.n. with the Protollin-formulated vaccine had significant levels of lung IgA, while i.n. immunized aged mice had no detectable virus titers after challenge with infectious SARS-CoV (strain Urbani). In contrast, young mice immunized i.m. with Alhydrogel-adsorbed vaccine did not show any detectable lung IgA, while virus titers in lungs of aged mice after challenge were comparable to those observed in control mice immunized with buffer or Protollin alone. The most protective immunization regimen appeared to be 30 μg ΔTM S protein administered i.n. in the presence of ProT adjuvant, based on average neutralizing antibody titers, average total IgG titers, and lack of detectable infectious virus in the lungs of challenged animals. Alhydrogel achieved protection from wild type virus challenge as well, although infectious virus was detected in the lungs of some animals in contrast to the Pro T adjuvant vaccine. The antibody was also neutralized the SARS-CoV Tor-II strain in vitro. Cytokines released by in vitro restimulated splenocytes collected from mice immunized with Protollin-formulated vaccine represented a balanced Th1/Th2 phenotype while a Th2-biased cytokine profile was observed for the intramuscular Alhydrogel-adsorbed vaccine. These data suggest that i.n. administered Protollin-formulated ΔTM S protein can elicit protective immunity against SARS-CoV infection in mice. Such a vaccine may serve as a useful template for the development of a SARS-CoV for humans.
